220 related articles for article (PubMed ID: 21704446)
1. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
Oechsle K; Kollmannsberger C; Honecker F; Mayer F; Waller CF; Hartmann JT; Boehlke I; Bokemeyer C;
Eur Urol; 2011 Oct; 60(4):850-5. PubMed ID: 21704446
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Seidel C; Oechsle K; Lorch A; Dieing A; Hentrich M; Hornig M; Grünwald V; Cathomas R; Meiler J; de Wit M; Bokemeyer C
Urol Oncol; 2016 Apr; 34(4):167.e21-8. PubMed ID: 26699830
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
Bokemeyer C; Oechsle K; Honecker F; Mayer F; Hartmann JT; Waller CF; Böhlke I; Kollmannsberger C;
Ann Oncol; 2008 Mar; 19(3):448-53. PubMed ID: 18006893
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Einhorn LH; Brames MJ; Juliar B; Williams SD
J Clin Oncol; 2007 Feb; 25(5):513-6. PubMed ID: 17290059
[TBL] [Abstract][Full Text] [Related]
5. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Beyer J; Liersch R; Schoeffski P; Metzner B; Hartmann JT; Rick O; Stengele K; Hohloch K; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2004 Jan; 22(1):108-14. PubMed ID: 14701772
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor.
De Giorgi U; Rosti G; Aieta M; Testore F; Burattini L; Fornarini G; Naglieri E; Lo Re G; Zumaglini F; Marangolo M
Eur Urol; 2006 Nov; 50(5):1032-8; discussion 1038-9. PubMed ID: 16757095
[TBL] [Abstract][Full Text] [Related]
7. Salvage chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) in relapsed or cisplatin-refractory germ cell tumors.
Park S; Lee S; Lee J; Park SH; Park JO; Kang WK; Park YS; Lim HY
Onkologie; 2011; 34(8-9):416-20. PubMed ID: 21934340
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
Farmakis D; Pectasides M; Pectasides D
Eur Urol; 2005 Sep; 48(3):400-7. PubMed ID: 15964136
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors.
Shiraishi T; Nakamura T; Mikami K; Takaha N; Kawauchi A; Miki T
Int J Clin Oncol; 2009 Oct; 14(5):436-41. PubMed ID: 19856053
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Mulherin BP; Brames MJ; Einhorn LH
Am J Clin Oncol; 2015 Aug; 38(4):373-6. PubMed ID: 26214082
[TBL] [Abstract][Full Text] [Related]
11. Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Fizazi K; Gravis G; Flechon A; Geoffrois L; Chevreau C; Laguerre B; Delva R; Eymard JC; Rolland F; Houede N; Laplanche A; Burcoveanu D; Culine S
Ann Oncol; 2014 May; 25(5):987-91. PubMed ID: 24595454
[TBL] [Abstract][Full Text] [Related]
12. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Kollmannsberger C; Rick O; Derigs HG; Schleucher N; Schöffski P; Beyer J; Schoch R; Sayer HG; Gerl A; Kuczyk M; Spott C; Kanz L; Bokemeyer C
J Clin Oncol; 2002 Apr; 20(8):2031-7. PubMed ID: 11956262
[TBL] [Abstract][Full Text] [Related]
13. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience.
De Giorgi U; Rosti G; Papiani G; Aieta M; Fochessati F; Paoluzzi L; Valduga F; Marangolo M
Am J Clin Oncol; 2004 Oct; 27(5):457-60. PubMed ID: 15596910
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.
Uchida M; Kawai K; Kimura T; Ichioka D; Takaoka E; Suetomi T; Miyazaki J; Nishiyama H
Int J Clin Oncol; 2014 Dec; 19(6):1112-7. PubMed ID: 24647526
[TBL] [Abstract][Full Text] [Related]
15. Platinum-refractory germ cell tumors: an update on current treatment options and developments.
Oing C; Alsdorf WH; von Amsberg G; Oechsle K; Bokemeyer C
World J Urol; 2017 Aug; 35(8):1167-1175. PubMed ID: 27449639
[TBL] [Abstract][Full Text] [Related]
16. Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Necchi A; Nicolai N; Mariani L; Lo Vullo S; Giannatempo P; Raggi D; Farè E; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Milani A; Gianni AM; Salvioni R
Clin Genitourin Cancer; 2014 Feb; 12(1):63-69.e1. PubMed ID: 24161525
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study.
Selle F; Wittnebel S; Biron P; Gravis G; Roubaud G; Bui BN; Delva R; Bay JO; Fléchon A; Geoffrois L; Caty A; Soares DG; de Revel T; Fizazi K; Gligorov J; Micléa JM; Dubot C; Provent S; Temby I; Gaulet M; Horn E; Brindel I; Lotz JP
Ann Oncol; 2014 Sep; 25(9):1775-1782. PubMed ID: 24894084
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
Nicolai N; Necchi A; Gianni L; Piva L; Biasoni D; Torelli T; Stagni S; Milani A; Pizzocaro G; Salvioni R
BJU Int; 2009 Aug; 104(3):340-6. PubMed ID: 19239440
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Skarlos D
Ann Oncol; 2004 Mar; 15(3):493-7. PubMed ID: 14998855
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours with high-dose chemotherapy as consolidation: a non-cisplatin-based induction approach.
Badreldin W; Krell J; Chowdhury S; Harland SJ; Mazhar D; Harding V; Frampton AE; Wilson P; Berney D; Stebbing J; Shamash J
BJU Int; 2016 Mar; 117(3):418-23. PubMed ID: 25430674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
